Biotech Values

[Mufaso]

NVO- CagriSema in phase 2 had these results in 32 weeks:

After 32 weeks of treatment, people treated with CagriSema achieved a numerically higher HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone. People treated with CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone1. In the trial, CagriSema appeared to have a safe and well-tolerated profile.

Looks like the weight loss efficacy of CagriSema is in the ballpark of LLY's Zepbound.